Overview Dividends

(ILMN) Illumina - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencers, Arrays, Consumables, Reagents, Library Prep

ILMN EPS (Earnings per Share)

EPS (Earnings per Share) of ILMN over the last years for every Quarter: "2020-09": 1.02, "2020-12": 1.22, "2021-03": 1.89, "2021-06": 1.87, "2021-09": 1.45, "2021-12": 0.75, "2022-03": 1.07, "2022-06": 0.57, "2022-09": 0.34, "2022-12": 0.14, "2023-03": 0.08, "2023-06": 0.32, "2023-09": 0.33, "2023-12": 0.14, "2024-03": 0.09, "2024-06": 0.36, "2024-09": 1.14, "2024-12": 0.86, "2025-03": 0.97, "2025-06": 1.19, "2025-09": 1.34,
EPS Growth (3Y CAGR): 127.36%
EPS Trend (3Y Correlation): 83.1%

ILMN Revenue

Revenue of ILMN over the last years for every Quarter: 2020-09: 794, 2020-12: 953, 2021-03: 1093, 2021-06: 1126, 2021-09: 1108, 2021-12: 1199, 2022-03: 1223, 2022-06: 1162, 2022-09: 1115, 2022-12: 1084, 2023-03: 1087, 2023-06: 1176, 2023-09: 1119, 2023-12: 1122, 2024-03: 1076, 2024-06: 1112, 2024-09: 1080, 2024-12: 1104, 2025-03: 1041, 2025-06: 1059, 2025-09: 1083,
Revenue Growth (3Y CAGR): -0.03%
Revenue Trend (3Y Correlation): -49.9%
Risk via 10d forecast
Volatility 42.8%
Value at Risk 5%th 66.3%
Relative Tail Risk -5.85%
Reward TTM
Sharpe Ratio -0.23
Alpha -33.47
Character TTM
Hurst Exponent 0.307
Beta 1.131
Beta Downside 1.063
Drawdowns 3y
Max DD 68.94%
Mean DD 39.35%
Median DD 42.51%

Description: ILMN Illumina October 30, 2025

Illumina, Inc. (NASDAQ: ILMN) designs, manufactures, and sells sequencing- and array-based platforms and consumables that enable whole-genome, exome, and targeted-region analysis for research, clinical, and consumer genomics applications across the Americas, Europe, Greater China, APAC, the Middle East, and Africa.

In FY 2023 the company generated roughly $4.5 billion in revenue, growing about 13 % year-over-year, with R&D expenditures representing ~20 % of sales-a reflection of its focus on maintaining a technological edge in next-generation sequencing (NGS). Illumina commands an estimated 70 % share of the global NGS market, driven by declining sequencing costs (now under $600 per human genome) and expanding clinical-diagnostic use cases such as non-invasive prenatal testing and oncology-focused liquid biopsies. The firm’s growth is also tied to broader sector trends, including increasing investment in personalized medicine and the rising demand for high-throughput genomic data in drug discovery.

For a deeper quantitative breakdown of Illumina’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard you may find useful.

ILMN Stock Overview

Market Cap in USD 18,626m
Sub-Industry Life Sciences Tools & Services
IPO / Inception 2000-07-28
Return 12m vs S&P 500 -26.0%
Analyst Rating 3.68 of 5

ILMN Dividends

Currently no dividends paid

ILMN Growth Ratios

CAGR 3y -17.60%
CAGR/Max DD Calmar Ratio -0.26
CAGR/Mean DD Pain Ratio -0.45
Current Volume 1063.2k
Average Volume 1319.1k

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (703.0m TTM) > 0 and > 6% of Revenue (6% = 257.2m TTM)
FCFTA 0.16 (>2.0%) and ΔFCFTA 7.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 19.45% (prev 31.85%; Δ -12.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.18 (>3.0%) and CFO 1.12b > Net Income 703.0m (YES >=105%, WARN >=100%)
Net Debt (1.53b) to EBITDA (1.27b) ratio: 1.20 <= 3.0 (WARN <= 3.5)
Current Ratio 1.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (157.0m) change vs 12m ago -1.88% (target <= -2.0% for YES)
Gross Margin 66.20% (prev 63.94%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 70.33% (prev 73.00%; Δ -2.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 7.96 (EBITDA TTM 1.27b / Interest Expense TTM 125.0m) >= 6 (WARN >= 3)

Altman Z'' 1.40

(A) 0.14 = (Total Current Assets 2.80b - Total Current Liabilities 1.96b) / Total Assets 6.18b
(B) -0.12 = Retained Earnings (Balance) -726.0m / Total Assets 6.18b
(C) 0.16 = EBIT TTM 995.0m / Avg Total Assets 6.10b
(D) -0.19 = Book Value of Equity -736.0m / Total Liabilities 3.80b
Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.89

1. Piotroski 8.0pt = 3.0
2. FCF Yield 5.02% = 2.51
3. FCF Margin 23.33% = 5.83
4. Debt/Equity 1.08 = 1.94
5. Debt/Ebitda 1.20 = 1.47
6. ROIC - WACC (= 6.59)% = 8.24
7. RoE 29.98% = 2.50
8. Rev. Trend -49.94% = -3.75
9. EPS Trend 83.07% = 4.15

What is the price of ILMN shares?

As of November 15, 2025, the stock is trading at USD 120.67 with a total of 1,063,200 shares traded.
Over the past week, the price has changed by -1.01%, over one month by +32.60%, over three months by +20.56% and over the past year by -15.16%.

Is Illumina a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Illumina (NASDAQ:ILMN) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.89 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ILMN is around 92.79 USD . This means that ILMN is currently overvalued and has a potential downside of -23.1%.

Is ILMN a buy, sell or hold?

Illumina has received a consensus analysts rating of 3.68. Therefor, it is recommend to hold ILMN.
  • Strong Buy: 7
  • Buy: 5
  • Hold: 11
  • Sell: 2
  • Strong Sell: 0

What are the forecasts/targets for the ILMN price?

Issuer Target Up/Down from current
Wallstreet Target Price 117.7 -2.4%
Analysts Target Price 117.7 -2.4%
ValueRay Target Price 104 -13.8%

ILMN Fundamental Data Overview November 10, 2025

Market Cap USD = 18.63b (18.63b USD * 1.0 USD.USD)
P/E Trailing = 27.3318
P/E Forward = 20.284
P/S = 4.3438
P/B = 6.7593
P/EG = 0.622
Beta = 1.45
Revenue TTM = 4.29b USD
EBIT TTM = 995.0m USD
EBITDA TTM = 1.27b USD
Long Term Debt = 1.49b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 2.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 19.92b USD (18.63b + Debt 2.58b - CCE 1.28b)
Interest Coverage Ratio = 7.96 (Ebit TTM 995.0m / Interest Expense TTM 125.0m)
FCF Yield = 5.02% (FCF TTM 1.00b / Enterprise Value 19.92b)
FCF Margin = 23.33% (FCF TTM 1.00b / Revenue TTM 4.29b)
Net Margin = 16.40% (Net Income TTM 703.0m / Revenue TTM 4.29b)
Gross Margin = 66.20% ((Revenue TTM 4.29b - Cost of Revenue TTM 1.45b) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 65.63%)
Tobins Q-Ratio = 3.23 (Enterprise Value 19.92b / Total Assets 6.18b)
Interest Expense / Debt = 1.94% (Interest Expense 50.0m / Debt 2.58b)
Taxrate = 31.82% (70.0m / 220.0m)
NOPAT = 678.4m (EBIT 995.0m * (1 - 31.82%))
Current Ratio = 1.43 (Total Current Assets 2.80b / Total Current Liabilities 1.96b)
Debt / Equity = 1.08 (Debt 2.58b / totalStockholderEquity, last quarter 2.38b)
Debt / EBITDA = 1.20 (Net Debt 1.53b / EBITDA 1.27b)
Debt / FCF = 1.53 (Net Debt 1.53b / FCF TTM 1.00b)
Total Stockholder Equity = 2.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.38% (Net Income 703.0m / Total Assets 6.18b)
RoE = 29.98% (Net Income TTM 703.0m / Total Stockholder Equity 2.35b)
RoCE = 25.95% (EBIT 995.0m / Capital Employed (Equity 2.35b + L.T.Debt 1.49b))
RoIC = 15.69% (NOPAT 678.4m / Invested Capital 4.32b)
WACC = 9.10% (E(18.63b)/V(21.20b) * Re(10.18%) + D(2.58b)/V(21.20b) * Rd(1.94%) * (1-Tc(0.32)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.63%
[DCF Debug] Terminal Value 70.95% ; FCFE base≈818.4m ; Y1≈822.4m ; Y5≈881.2m
Fair Price DCF = 71.81 (DCF Value 10.97b / Shares Outstanding 152.8m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: 83.07 | EPS CAGR: 127.4% | SUE: 0.67 | # QB: 0
Revenue Correlation: -49.94 | Revenue CAGR: -0.03% | SUE: 1.05 | # QB: 1

Additional Sources for ILMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle